You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study
|
|---|---|
| Published in |
Lancet Oncology, February 2012
|
| DOI | 10.1016/s1470-2045(12)70049-9 |
| Pubmed ID | |
| Authors |
Jean-Yves Pierga, Thierry Petit, Thierry Delozier, Jean-Marc Ferrero, Mario Campone, Joseph Gligorov, Florence Lerebours, Henri Roché, Thomas Bachelot, Emmanuelle Charafe-Jauffret, Maria Pavlyuk, Sandrine Kraemer, François-Clément Bidard, Patrice Viens |
| Abstract |
Bevacizumab and trastuzumab are efficacious for treatment of advanced or HER2-positive metastatic breast cancer; however, few data exist for this regimen in inflammatory breast cancer. In our phase 2 trial, we aimed to assess efficacy and safety of neoadjuvant bevacizumab combined with trastuzumab and chemotherapy in patients with primary HER2-positive inflammatory breast cancer. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| South Africa | 1 | 50% |
| United States | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 112 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 2 | 2% |
| Brazil | 2 | 2% |
| Ireland | 1 | <1% |
| Germany | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 105 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 23 | 21% |
| Other | 17 | 15% |
| Student > Ph. D. Student | 17 | 15% |
| Student > Master | 9 | 8% |
| Student > Bachelor | 9 | 8% |
| Other | 18 | 16% |
| Unknown | 19 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 56 | 50% |
| Agricultural and Biological Sciences | 11 | 10% |
| Biochemistry, Genetics and Molecular Biology | 5 | 4% |
| Nursing and Health Professions | 4 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Other | 6 | 5% |
| Unknown | 26 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 December 2013.
All research outputs
#15,229,642
of 25,460,914 outputs
Outputs from Lancet Oncology
#4,870
of 6,901 outputs
Outputs of similar age
#97,924
of 168,267 outputs
Outputs of similar age from Lancet Oncology
#57
of 98 outputs
Altmetric has tracked 25,460,914 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 6,901 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.2. This one is in the 27th percentile – i.e., 27% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 168,267 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 98 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.